(2023)
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Genome Medicine.
15,
1
(2023)
The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling.
JCI INSIGHT.
8,
21
(2023)
Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus.
MOLECULAR THERAPY-ONCOLYTICS.
30,
(2021)
Development of a new advanced animal cradle for small animal multiple imaging modalities: acquisition and evaluation of high-throughput multiple-mouse imaging.
PHYSICAL AND ENGINEERING SCIENCES IN MEDICINE.
44,
4
(2018)
Innovative Distribution Priorities for the Medical Devices Indus ry in the Fourth Industrial Revolution.
INTERNATIONAL NEUROUROLOGY JOURNAL.
22,
(2018)
Pharmacokinetics, Biodistribution, and Toxicity Evaluation of Anti-SEMA3A (F11) in In Vivo Models.
ANTICANCER RESEARCH.
38,
5
(2017)
Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.
494,
1-2
(2017)
Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress GBM Tumor Growth..
CANCER RESEARCH AND TREATMENT.
.,
.
(2017)
Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
18,
9
(2016)
GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands..
MOLECULAR CANCER THERAPEUTICS.
15,
2
(2015)
Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
BMC CANCER.
15,
(2015)
GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
MOLECULAR CANCER THERAPEUTICS.
15,
2
(2015)
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
CANCER CELL.
28,
3
(2015)
USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.
NEURO-ONCOLOGY.
18,
1
(2015)
In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma.
ONCOTARGET.
6,
24
(2014)
Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.
ONCOTARGETS AND THERAPY.
7,
(2014)
Translational Validation of Personalized Treatment Strategy Based on Genetic Characteristics of Glioblastoma.
PLOS ONE.
9,
8
